• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Establishment and therapeutic application of a new clinical staging system based on the biological features of pancreatic adenocarcinoma

Research Project

Project/Area Number 17K09459
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Gastroenterology
Research InstitutionMie University

Principal Investigator

Isaji Shuji  三重大学, 医学部附属病院, 病院長 (70176121)

Co-Investigator(Kenkyū-buntansha) 村田 泰洋  三重大学, 医学部附属病院, 講師 (20572655)
水野 修吾  三重大学, 医学系研究科, 教授 (70335131)
岸和田 昌之  三重大学, 医学部附属病院, 准教授 (40501961)
加藤 宏之  三重大学, 医学部附属病院, 助教 (50737004)
Project Period (FY) 2017-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Keywords浸潤性膵管癌 / 生物学的悪性度 / 化学放射線治療 / 免疫栄養指標 / 局所進行切除不能膵癌 / 境界切除可能膵癌 / 局所進行膵癌 / 新規臨床病期システム
Outline of Final Research Achievements

Preoperative chemoradiotherapy (CRT) offers benefits, including downstaging of the primary tumor with a consequent reduction in the risks of a microscopically positive resection for the patients with localized pancreatic adenocarcinoma (PDAC). However, the prognosis of the localized PDAC patients who could not undergo resection after CRT because of local progression and distant metastasis is usually dismal. This study aimed to clarify the clinicopathological features of localized PDAC that was resistant to CRT or have distant occult metastasis. We reported that the international consensus on the definition of borderline resectable PDAC based on anatomical, biological, and conditional factors, was associated with prognosis after CRT and the prognostic nutritional index after CRT was the strongest prognostic factor among the conditional factors. We reported that CEA value before preoperative CRT was a crucial prognostic indicator for the patients with locally advanced unresectable PDAC.

Academic Significance and Societal Importance of the Research Achievements

本研究の結果、術前化学放射線治療に耐性を示し、潜在性微小遠隔転移が顕在化したため、非切除となった予後不良な局所性膵癌の生物学的特性や宿主の因子を新たに同定した。膵癌のさらなる治療成績向上のためには、個々の腫瘍の生物学的悪性度ならびに宿主の免疫栄養指標に基づいた膵癌の臨床病期システムとそれに基づいた治療プロトコールの確立が急務であり、本研究の成果は今後さらなる臨床応用が期待され、膵癌の予後改善に貢献することが期待される。

Report

(5 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (29 results)

All 2020 2019 2018 2017

All Journal Article (10 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 10 results,  Open Access: 5 results) Presentation (19 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma2020

    • Author(s)
      Kato Hiroyuki、Kishiwada Masashi、Hayasaki Aoi、Chipaila Jackson、Maeda Koki、Noguchi Daisuke、Gyoten Kazuyuki、Fujii Takehiro、Iizawa Yusuke、Tanemura Akihiro、Murata Yasuhiro、Kuriyama Naohisa、Usui Masanobu、Sakurai Hiroyuki、Isaji Shuji、Mizuno Shugo
    • Journal Title

      Annals of Surgery

      Volume: - Issue: 5 Pages: e698-e707

    • DOI

      10.1097/sla.0000000000004148

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor2019

    • Author(s)
      Takeuchi Taijiro、Mizuno Shugo、Murata Yasuhiro、Hayasaki Aoi、Kishiwada Masashi、Fujii Takehiro、Iizawa Yusuke、Kato Hiroyuki、Tanemura Akihiro、Kuriyama Naohisa、Azumi Yoshinori、Usui Masanobu、Sakurai Hiroyuki、Isaji Shuji
    • Journal Title

      Pancreas

      Volume: 48(2) Issue: 2 Pages: 281-291

    • DOI

      10.1097/mpa.0000000000001227

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy2019

    • Author(s)
      Jaseanchiun Warakorn、Kato Hiroyuki、Hayasaki Aoi、Fujii Takehiro、Iizawa Yusuke、Tanemura Akihiro、Murata Yasuhiro、Azumi Yoshinori、Kuriyama Naohisa、Kishiwada Masashi、Mizuno Shugo、Usui Masanobu、Sakurai Hiroyuki、Isaji Shuji
    • Journal Title

      Pancreatology

      Volume: 19(2) Issue: 2 Pages: 307-315

    • DOI

      10.1016/j.pan.2019.01.020

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients2019

    • Author(s)
      Ichikawa Ken、Mizuno Shugo、Hayasaki Aoi、Kishiwada Masashi、Fujii Takehiro、Iizawa Yusuke、Kato Hiroyuki、Tanemura Akihiro、Murata Yasuhiro、Azumi Yoshinori、Kuriyama Naohisa、Usui Masanobu、Sakurai Hiroyuki、Isaji Shuji
    • Journal Title

      Cancers

      Volume: 11(4) Issue: 4 Pages: 514-514

    • DOI

      10.3390/cancers11040514

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes2019

    • Author(s)
      Hayasaki Aoi、Murata Yasuhiro、Usui Masanobu、Hibi Taemi、Fujii Takehiro、Iizawa Yusuke、Kato Hiroyuki、Tanemura Akihiro、Azumi Yoshinori、Kuriyama Naohisa、Kishiwada Masashi、Mizuno Shugo、Sakurai Hiroyuki、Uchida Katsunori、Isaji Shuji
    • Journal Title

      BioMed Research International

      Volume: 2019 Pages: 1-12

    • DOI

      10.1155/2019/5738614

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients.2019

    • Author(s)
      Ichikawa K, Mizuno S, Hayasaki A, Kishiwada M, Fujii T, Iizawa Y, Kato H, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Usui M, Sakurai H, Isaji S
    • Journal Title

      Cancers (Basel).

      Volume: 11(4).

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor.2019

    • Author(s)
      Takeuchi T, Mizuno S, Murata Y, Hayasaki A, Kishiwada M, Fujii T, Iizawa Y, Kato H, Tanemura A, Kuriyama N, Azumi Y, Usui M, Sakurai H, Isaji S.
    • Journal Title

      Pancreas.

      Volume: 48(2) Pages: 281-291

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy.2019

    • Author(s)
      Jaseanchiun W, Kato H, Hayasaki A, Fujii T, Iizawa Y, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Kishiwada M, Mizuno S, Usui M, Sakurai H, Isaji S.
    • Journal Title

      Pancreatology.

      Volume: 19(2) Pages: 307-315

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer.2018

    • Author(s)
      Hayasaki A, Isaji S, Kishiwada M, Fujii T, Iizawa Y, Kato H, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Mizuno S, Usui M, Sakurai H.
    • Journal Title

      Cancers (Basel).

      Volume: 10(3)

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.2018

    • Author(s)
      Isaji S, Mizuno S, Windsor JA, Bassi C, Fernandez-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW, Kishiwada M, Kitagawa H, Michalski CW, Wolfgang CL.
    • Journal Title

      Pancreatology.

      Volume: 18(1) Pages: 2-11

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] 切除可能膵癌に対する術前化学放射線治療の臨床的意義 up-front surgeryとの後方視的比較検討2020

    • Author(s)
      村田 泰洋, 尭天 一亨, 早崎 碧泉, 藤井 武宏, 飯澤 祐介, 種村 彰洋, 栗山 直久, 岸和田 昌之, 櫻井 洋至, 水野 修吾
    • Organizer
      第75回日本消化器外科学会総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 進行膵癌に対するConversion surgery 局所進行膵癌に対する化学放射線先行療法後の治療成績-診断時因子に注目して2020

    • Author(s)
      岸和田 昌之, 早崎 碧泉, 尭天 一亨, 藤井 武宏, 飯澤 祐介, 村田 泰洋, 種村 彰洋, 栗山 直久, 櫻井 洋至, 水野 修吾
    • Organizer
      第75回日本消化器外科学会総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 切除可能膵癌における術前化学放射線治療の治療成績 biological borderline膵癌に対する有効性の検討2020

    • Author(s)
      村田 泰洋, 早崎 碧泉, 飯澤 裕介, 藤井 武宏, 加藤 宏之, 種村 彰洋, 栗山 直久, 岸和田 昌之, 水野 修吾, 櫻井 洋至, 伊佐地 秀司
    • Organizer
      第120回日本外科学会定期学術集会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 長期成績からみた膵癌に対する集学的治療の評価 局所進行切除不能膵癌に対する化学放射線先行療法後の治療成績2020

    • Author(s)
      岸和田 昌之, 早崎 碧泉, 藤井 武宏, 飯澤 祐介, 加藤 宏之, 村田 泰洋, 種村 彰洋, 栗山 直久, 水野 修吾, 櫻井 洋至, 伊佐地 秀司
    • Organizer
      第120回日本外科学会定期学術集会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 局所進行膵癌に対するgemcitabine+S1併用放射線化学療法の予後予測 EUS-FNAB検体中hENT1・DPD発現と予後との関連性2020

    • Author(s)
      山田 玲子, 服部 愛司, 倉田 一成, 重福 亜紀奈, 坪井 順哉, 井上 宏之, 早崎 碧泉, 村田 泰洋, 岸和田 昌之, 水野 修吾, 伊佐地 秀司, 竹井 謙之
    • Organizer
      第106回日本消化器病学会総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 切除可能境界膵癌に対する術前化学放射線療法の治療成績2019

    • Author(s)
      村田 泰洋, 早崎 碧泉, 伊佐地 秀司
    • Organizer
      第105回日本消化器病学会総会
    • Related Report
      2019 Research-status Report
  • [Presentation] 切除可能膵癌における術前化学放射線治療の臨床的意義 術後早期再発症例の検討2019

    • Author(s)
      村田 泰洋, 早崎 碧泉, 飯澤 裕介, 藤井 武宏, 加藤 宏之, 種村 彰洋, 栗山 直久, 安積 良紀, 岸和田 昌之, 水野 修吾, 臼井 正信, 櫻井 洋至, 伊佐地 秀司
    • Organizer
      第119回日本外科学会定期学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] 局所進行切除不能膵癌に対するConversion surgeryの適応決定における術前癌胎児性抗原(CEA)の重要性 術直前CEA値と切除後予後に着目した臨床的研究2019

    • Author(s)
      加藤 宏之, 岸和田 昌之, 早崎 碧泉, 藤井 武宏, 飯澤 祐介, 村田 泰洋, 種村 彰洋, 安積 良紀, 栗山 直久, 水野 修吾, 臼井 正信, 櫻井 洋至, 伊佐地 秀司
    • Organizer
      第119回日本外科学会定期学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] 局所進行膵癌に対する術前化学放射線療法の治療成績 動脈浸潤と組織学効果に注目して2019

    • Author(s)
      岸和田 昌之, 早崎 碧泉, 藤井 武宏, 飯澤 祐介, 加藤 宏之, 村田 泰洋, 種村 彰洋, 栗山 直久, 安積 良紀, 水野 修吾, 臼井 正信, 櫻井 洋至, 伊佐地 秀司
    • Organizer
      第50回日本膵臓学会大会
    • Related Report
      2019 Research-status Report
  • [Presentation] Impact of preoperative chemoradiotherapy for unresectable locally advanced pancreatic cancer paying attention to pre- and post-CRT biological and conditional factors2019

    • Author(s)
      Masashi Kishiwada, Aoi Hayasaki, Takehiro Fujii, Yusuke Iizawa, Hiroyuki Kato, Yasuhiro Murata, Akihiro Tanemura, Naohisa Kuriyama, Yoshinori Azumi, Shugo Mizuno, Masanobu Usui, Hiroyuki Sakurai, Shuuji Isaji
    • Organizer
      第31回日本肝胆膵外科学会・学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] Treatment strategy for R and BR pancreatic cancer patients undergoing preoperative chemoradiotherapy according to anatomical, biological and conditional factors2019

    • Author(s)
      Shugo Mizuno, Aoi Hayasaki, Masashi Kishiwada, Hiroyuki Kato, Takehiro Fujii, Yusuke Iizawa, Yasuhiro Murata, Akihiro Tanemura, Naohisa Kuriyama, Yoshinori Azumi, Masanobu Usui, Hiroyuki Sakurai, Shuji Isaji
    • Organizer
      第31回日本肝胆膵外科学会・学術集会
    • Related Report
      2019 Research-status Report
  • [Presentation] Borderline resectable膵癌の国際コンセンサス2017からみた局所性膵癌の治療戦略2018

    • Author(s)
      伊佐地 秀司、水野 修吾、岸和田 昌之、早崎 碧泉
    • Organizer
      第49回日本膵臓学会大会
    • Related Report
      2018 Research-status Report
  • [Presentation] 局所性膵癌に対する化学放射線療法施行例における炎症/免疫栄養指標と予後の関係2018

    • Author(s)
      市川 健、水野 修吾、早崎 碧泉、岸和田 昌之、飯澤 祐介、加藤 宏之、村田 泰洋、種村 彰洋、栗山 直久、臼井 正信、櫻井 洋至、伊佐地 秀司
    • Organizer
      第49回日本膵臓学会大会
    • Related Report
      2018 Research-status Report
  • [Presentation] 放射線化学療法の抗腫瘍効果に着目した膵癌治療前予後予測におけるノモグラムの有用性2018

    • Author(s)
      加藤 宏之、岸和田 昌之、早崎 碧泉、藤井 武宏、飯澤 祐介、種村 彰洋、村田 泰洋、栗山 直久、安積 良紀、水野 修吾、臼井 正信、櫻井 洋至、小椋 透、伊佐地 秀司
    • Organizer
      第49回日本膵臓学会大会
    • Related Report
      2018 Research-status Report
  • [Presentation] 局所進行膵癌患者における化学放射線治療施行前後での炎症/免疫栄養指標と予後との関連性について2018

    • Author(s)
      市川 健、水野修吾、早崎碧泉、岸和田昌之、飯澤祐介、加藤宏之、村田泰洋、種村彰洋、栗山直久、臼井正信、櫻井洋至、伊佐地秀司
    • Organizer
      第118回日本外科学会
    • Related Report
      2017 Research-status Report
  • [Presentation] 局所進行膵癌の治療前予後予測を目的としたPredictive nomogramの作成2017

    • Author(s)
      加藤 宏之、岸和田昌之、水野修吾、尭天一亨、早崎碧泉、飯澤祐介、種村彰洋、村田泰洋、安積良紀、栗山直久、臼井正信、櫻井洋至、小倉 透、伊佐地秀司
    • Organizer
      JDDW2017
    • Related Report
      2017 Research-status Report
  • [Presentation] 局所進行膵癌に対する治療前予後予測は可能か?- 放射線化学療法前予後因子の解析とpredictive nomogramの作成-2017

    • Author(s)
      加藤 宏之、岸和田昌之、尭天一亨、早崎碧泉、松井俊樹、飯澤祐介、種村彰洋、村田泰洋、安積良紀、栗山直久、水野修吾、臼井正信、櫻井洋至、伊佐地秀司、小椋 透
    • Organizer
      第117回日本外科学会
    • Related Report
      2017 Research-status Report
  • [Presentation] 局所進行膵癌における術前放射線化学療法施行後、遠隔転移発生の危険因子解析2017

    • Author(s)
      加藤 宏之、水野修吾、早崎碧泉、尭天一亨、飯澤祐介  種村彰洋、村田泰洋、安積良紀、栗山直久、岸和田昌之、臼井正信、櫻井洋至、伊佐地秀司
    • Organizer
      第48回日本膵臓学会大会
    • Related Report
      2017 Research-status Report
  • [Presentation] Predictive nomogram for interval distant metastases of locally advanced pancreatic ductal carcinoma after preoperative gemcitabine based chemoradiotherapy. -Clinical importance of biological and physiological markers-2017

    • Author(s)
      加藤 宏之、水野修吾、小倉 透、早崎碧泉、岸和田昌之、栗山直久、安積良紀、臼井正信、櫻井洋至、伊佐地秀司
    • Organizer
      第29回 肝胆膵外科学会
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2017-04-28   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi